Xin Lang Cai Jing·2026-02-24 15:23Core Viewpoint - Gilead Sciences has agreed to acquire Arcellx for $115 per share in cash, with potential additional contingent payments of up to $5 per share, implying a total value of $7.8 billion for the deal, aimed at gaining full control of the BCMA CAR-T therapy anito-cel for multiple myeloma, with an FDA PDUFA date set for December 23, 2026 [1] Summary by Category - Acquisition Details - Gilead Sciences will pay $115 in cash per share for Arcellx [1] - There is a potential for additional contingent payments of up to $5 per share [1] - The total implied value of the acquisition is $7.8 billion [1] - Product Information - The acquisition includes full control of the BCMA CAR-T therapy anito-cel [1] - The FDA PDUFA date for anito-cel is December 23, 2026 [1]